Replies to post #172997 on Biotech Values

[DewDiligence]

% GT1 starts on Sovaldi: My guess would be close to 50%.

I’m asking for your estimate of the % of 2014 Sovaldi starts that are for GT1 patients—not the % of 2014 GT1 patients who start treatment on Sovaldi. Also, I’m interested in the worldwide %, not the one for the US market. T.i.a.